Challenges of corneal infections

References

• Gaujoux T, Chatel MA, Chaumeil C, et al. Outbreak of contact lens-related Fusarium keratitis in France. Cornea. 2008;27:1018–1021.
   PubMed Web of Science ®Google Scholar
• Chang DC, Grant GB, O’Donnell K, et al. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA. 2006;296:953–963.
   PubMed Web of Science ®Google Scholar
• Khor WB, Aung T, Saw SM, et al. An outbreak of Fusarium keratitis associated with contact lens wear in Singapore. JAMA. 2006;295:2867–2873.
   PubMed Web of Science ®Google Scholar
• Imamura Y, Chandra J, Mukherjee PK, et al. Fusarium and Candida albicans biofilms on soft contact lenses: model development, influence of lens type, and susceptibility to lens care solutions. Antimicrob Agents Chemother. 2008;52:171–182.
   PubMed Web of Science ®Google Scholar
• Bharathi MJ, Ramakrishnan R, Meenakshi R, et al. Microbial keratitis in South India: influence of risk factors, climate, and geographical variation. Ophthalmic Epidemiol. 2007;14:61–69.
   PubMed Web of Science ®Google Scholar
• Bharathi MJ, Ramakrishnan R, Meenakshi R, et al. Analysis of the risk factors predisposing to fungal, bacterial and Acanthamoeba keratitis in south India. Indian J Med Res. 2009;130:749–757.
   PubMed Web of Science ®Google Scholar
• Xie L, Zhong W, Shi W, et al. Spectrum of fungal keratitis in north China. Ophthalmology. 2006;113:1943–1948.
   PubMed Web of Science ®Google Scholar
• Wang L, Sun S, Jing Y, et al. Spectrum of fungal keratitis in central China. Clin Exp Ophthalmol. 2009;37:763–771.
   PubMed Web of Science ®Google Scholar
• Oliveira M, Ribeiro H, Delgado JL, et al. The effects of meteorological factors on airborne fungal spore concentration in two areas differing in urbanisation level. Int J Biometeorol. 2009;53:61–73.
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis. 2007;45:673–681.
   PubMed Web of Science ®Google Scholar
• Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol. 2008;126:155–164.
   PubMed Web of Science ®Google Scholar
• Gallien S, Fournier S, Porcher R, et al. Therapeutic outcome and prognostic factors of invasive aspergillosis in an infectious disease department: a review of 34 cases. Infection. 2008;36:533–538.
   PubMed Web of Science ®Google Scholar
• Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med. 1991;324:654–662.
   PubMed Web of Science ®Google Scholar
• Leal SM Jr, Vareechon C, Cowden S, et al. Fungal antioxidant pathways promote survival against neutrophils during infection. J Clin Invest. 2012;122:2482–2498.
   PubMed Web of Science ®Google Scholar
• Clark HL, Jhingran A, Sun Y, et al. Zinc and manganese chelation by neutrophil S100A8/A9 (calprotectin) limits extracellular Aspergillus fumigatus hyphal growth and corneal infection. J Immunol. 2016;96:336–344.
   Web of Science ®Google Scholar
• Leal SM Jr, Roy S, Vareechon C, et al. Targeting iron acquisition blocks infection with the fungal pathogens Aspergillus fumigatus and Fusarium oxysporum. PLoS Pathog. 2013;9(7):e1003436. doi:10.1371/journal.ppat.1003436.
   PubMed Web of Science ®Google Scholar
• Taylor PR, Leal SM Jr, Sun Y, et al. Aspergillus and Fusarium corneal infections are regulated by Th17 cells and IL-17 producing neutrophils. J Immunol. 2014;192(7):3319–3327.
   PubMed Web of Science ®Google Scholar
• Karthikeyan RS, Leal SM Jr, Prajna NV, et al. Expression of innate and adaptive immune mediators in human corneal tissue infected with Aspergillus or Fusarium. J Inf Dis. 2015;211:130–134.
   PubMed Web of Science ®Google Scholar
• Netea MG, Brown GD, Kullberg BJ, et al. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol. 2008;6:67–78.
   PubMed Web of Science ®Google Scholar
• Netea MG, Gow NA, Munro CA, et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest. 2006;116:1642–1650.
   PubMed Web of Science ®Google Scholar
• Jouault T, Ibata-Ombetta S, Takeuchi O, et al. Candida albicans phospholipomannan is sensed through Toll-like receptors. J Infect Dis. 2003;188:165–172.
   PubMed Web of Science ®Google Scholar
• Brown GD, Herre J, Williams DL, et al. Dectin-1 mediates the biological effects of beta glucans. J Exp Med. 2003;197:1119–1124.
   PubMed Web of Science ®Google Scholar
• Gantner BN, Simmons RM, Canavera SJ, et al. Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med. 2003;197:1107–1117.
   PubMed Web of Science ®Google Scholar
• Taylor PR, Tsoni SV, Willment JA, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol. 2007;8:31–38.
   PubMed Web of Science ®Google Scholar
• Saijo S, Fujikado N, Furuta T, et al. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol. 2007;8:39–46.
   PubMed Web of Science ®Google Scholar
• Dennehy KM, Ferwerda G, Faro-Trindade I, et al. Syk kinase is required for collaborative cytokine production induced through Dectin-1 and Toll-like receptors. Eur J Immunol. 2008;38:500–506.
   PubMed Web of Science ®Google Scholar
• Gow NA, Netea MG, Munro CA, et al. Immune recognition of Candida albicans beta-glucan by dectin-1. J Infect Dis. 2007;196:1565–1571.
   PubMed Web of Science ®Google Scholar
• Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Eng J Med. 2009;361:1760–1767.
   PubMed Web of Science ®Google Scholar
• Evans DJ, Fleiszig SMJ. Microbial keratitis: could contact lens material affect disease pathogenesis? Eye Contact Lens. 2013;39(1):73–78.
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Chandra J, Yu C, et al. Characterization of Fusarium keratitis outbreak isolates: contribution of biofilms to antimicrobial resistance and pathogenesis. Invest Ophthalmol Vis Sci. 2012;53:4450–4457.
   PubMed Web of Science ®Google Scholar
• FlorCruz NV, Evans JR. Medical interventions for fungal keratitis. Cochrane Database Syst Rev. 2015;4:CD004241. doi:10.1002/14651858.CD004241.pub4.
   Google Scholar
• Chandasana H, Prasad YD, Chhonker YS, et al. Corneal targeted nanoparticles for sustained natamycin delivery and their PK/PD indices: an approach to reduce dose and dosing frequency. Internl J Pharm. 2014;477:317–325.
   PubMed Web of Science ®Google Scholar
• Deschênes J, Blondeau J. Besifloxacin in the management of bacterial infections of the ocular surface. Can J Ophthalmol. 2015;50(3):184–191.
   PubMed Web of Science ®Google Scholar
• Schechter BA, Parekh JG, Trattler W. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study. J Ocular Pharmacol Ther. 2015;31(2):114–121.
   PubMed Web of Science ®Google Scholar
• Chatterjee SS, Otto M. How can Staphylococcus aureus phenol-soluble modulins be targeted to inhibit infection? Future Microbiol. 2013;8(6):693–696.
   PubMed Web of Science ®Google Scholar
• Laventie BJ, Rademaker HJ, Saleh M, et al. Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins. PNAS. 2011;108(39):16404–16409.
   PubMed Web of Science ®Google Scholar
• Mah FS, Davidson R, Holland EJ, et al. Current knowledge about and recommendations for ocular methicillin-resistant Staphylococcus aureus. J Cataract Refract Surg. 2014;40:1894–1908.
   PubMed Web of Science ®Google Scholar
• Lee JE, Sun Y, Gjorstrup P, et al. Inhibition of corneal inflammation by the resolvin E1. Invest Ophthalmol Vis Sci. 2015;56:2728–2736.
   PubMed Web of Science ®Google Scholar
• Solanki S, Rathi M, Khanduja S, et al. Recent trends: medical management of infectious keratitis. Oman J Ophthalmol. 2015;8:83–85.
   PubMedGoogle Scholar
• Tabibian D, Richoz O, Hafezi F. PACK-CXL: corneal cross-linking for treatment of infectious keratitis. J Ophthalmic Vis Res. 2015;10:77–80.
   PubMedGoogle Scholar
• Tabibian D, Mazzota C, Hafezi F. PACK-CXL: corneal cross-linking in infectious keratitis. Eye Vis (London). 2016;19:3–11.
   Google Scholar
• Tal K, Gal-Or O, Pillar S, et al. Efficacy of primary collagen cross-linking with photoactivated chromophore (PACK-CXL) for the treatment of Staphylococcus aureus-induced corneal ulcers. Cornea. 2015;34(10):1281–1286.
   PubMed Web of Science ®Google Scholar
• Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol. 2007;1(4):441–453.
   PubMedGoogle Scholar
• Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol. 1999;237(5):435–438.
   PubMed Web of Science ®Google Scholar
• Cope JR, Collier AS, Rao MM, et al. Contact lens wearer demographics and risk behaviors for contact lens-related eye infections – United States, 2014. CDC-MMWR. 2015;64(32):865–870.
   PubMed Web of Science ®Google Scholar
• Bouhenni R, Dunmire J, Rowe T, et al. Proteomics in the study of bacterial keratitis. Proteomes. 2015;3:496–511.
   Google Scholar
• Chang VS, Dhaliwal DK, Raju L, et al. Antibiotic resistance in the treatment of Staphylococcus aureus keratitis: a 20-year review. Cornea. 2015;34(6):698–703.
   PubMed Web of Science ®Google Scholar
• Rhem MN, Lech EM, Patti JM, et al. The collagen-binding adhesion is a virulence factor in Staphylococcus aureus keratitis. Infect Immun. 2000;68(6):3776–3779.
   PubMed Web of Science ®Google Scholar
• Jett BD, Gilmore MS. Internalization of Staphylococcus aureus by human corneal epithelial cells: role of bacterial fibronectin-binding proteins and host cell factors. Infect Immun. 2002;70(8):4697–4700.
   PubMed Web of Science ®Google Scholar
• Otto M. Staphylococcus aureus toxins. Curr Opin Microbiol. 2014;17:32–37.
   PubMed Web of Science ®Google Scholar
• O’Callaghan RJ, Callegan MC, Moreau JM, et al. Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus cornea infection. Infect Immun. 1997;65(5):1571–1578.
   PubMed Web of Science ®Google Scholar
• Inoshima I, Inoshima N, Wilke GA, et al. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med. 2011;17(10):1310–1314.
   PubMed Web of Science ®Google Scholar
• Wilke GA, Bubeck Wardenburg J. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. PNAS. 2010;107(30):13473–13478.
   PubMed Web of Science ®Google Scholar
• Nygaard TK, Pallister KB, DuMont AL, et al. Alpha-toxin induces programmed cell death of human T cells, B cells, and monocytes during USA300 infection. PLos One. 2012;7(5):e36532.
   PubMed Web of Science ®Google Scholar
• Hume EBH, Cole N, Khan S, et al. A Staphylococcus aureus mouse keratitis topical infection model: cytokine balance in different strains of mice. Immunol Cell Biol. 2005;83:294–300.
   PubMed Web of Science ®Google Scholar
• Gokhale NS. Medical management approach to infectious keratitis. Indian J Ophthalmol. 2008;56:215–220.
   PubMed Web of Science ®Google Scholar
• Segreti J, Jones RN, Bertino JS. Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones. J Ocul Pharmacol Ther. 2012;28(1):3–11.
   PubMed Web of Science ®Google Scholar
• Srinivasan M, Mascarenhas J, Rajaraman R, et al. Corticosteriods for bacterial keratitis: the steroids for corneal ulcers trial (SCUT). Arch Ophthalmol. 2012;130:143–150.
   PubMed Web of Science ®Google Scholar
• Vuong C, Yeh AJ, Cheung GTC, et al. Investigational drugs to treat methicillin-resistant Staphylococcus aureus. Expert Opin Investig Drugs. 2016;25(1):73–93.
   PubMed Web of Science ®Google Scholar
• Willcox MD. Management and treatment of contact lens-related Pseudomonas keratitis. Clin Ophthalmol. 2012;6:919–924.
   PubMedGoogle Scholar
• Hoge R, Pelzer A, Rosenau F, et al. Weapons of a pathogen: proteases and their role in virulence of Pseudomonas aeruginosa. In: Mendez-Vilas A, editor. Current research, technology and education topics in applied microbiology and microbial biotechnology, number 2. Microbiology book series. Badajoz: Formatex Research Center; 2010. p. 383–395.
   Google Scholar
• Hazlett LD. Corneal response to Pseudomonas aeruginosa infection. Prog Retin Eye Res. 2004;23:1–30.
   PubMed Web of Science ®Google Scholar
• Eby AM, Hazlett LD. Pseudomonas keratitis, a review of where we’ve been and what lies ahead. J Microb Biochem Technol. 2015;7:453–457.
   Google Scholar
• Sun Y, Karmakar M, Taylor PR, et al. ExoS and ExoT ADP ribosyltransferase activities mediate Pseudomonas aeruginosa keratitis by promoting neutrophil apoptosis and bacterial survival. J Immunol. 2012;188:1884–1895.
   PubMed Web of Science ®Google Scholar
• Pearlman E, Sun Y, Roy S, et al. Host defense at the ocular surface. Int Rev Immunol. 2013;32:4–18.
   PubMed Web of Science ®Google Scholar
• Berger EA, McClellan SA, Vistisen KS, et al. HIF-1alpha is essential for effective PMN bacterial killing, antimicrobial peptide production and apoptosis in Pseudomonas aeruginosa keratitis. PLoS Pathog. 2013;9:e1003457.
   PubMed Web of Science ®Google Scholar
• Suryawanshi A, Cao Z, Thitiprasert T, et al. Galectin-1-mediated suppression of Pseudomonas aeruginosa-induced corneal immunopathology. J Immunol. 2013;190:6397–6409.
   PubMed Web of Science ®Google Scholar
• Foldenauer ME, McClellan SA, Berger EA, et al. Mammalian target of rapamycin regulates IL-10 and resistance to Pseudomonas aeruginosa corneal infection. J Immunol. 2013;190:5649–5658.
   PubMed Web of Science ®Google Scholar
• Breidenstein EB, de la Fuente-Nunez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19:419–426.
   PubMed Web of Science ®Google Scholar
• Fernandes M, Vira D, Medikonda R, et al. Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome. Graefes Arch Clin Exp Ophthalmol. 2015;254:315–322.
   PubMed Web of Science ®Google Scholar
• Sharma N, Jindal A, Bali SJ, et al. Recalcitrant Pseudomonas keratitis after epipolis laser-assisted in situ keratomileusis: case report and review of the literature. Clin Exp Optom. 2012;95:460–463.
   PubMed Web of Science ®Google Scholar
• Tallab RT, Stone DU. Corticosteroids as a therapy for bacterial keratitis: an evidence-based review of ‘who, when and why’. Br J Ophthalmol. 2016;100:731–735. Epub 2016 Jan 7. doi:10.1136/bjophthalmol-2015-307955.
   PubMed Web of Science ®Google Scholar
• Sy A, Srinivasan M, Mascarenhas J, et al. Pseudomonas aeruginosa keratitis: outcomes and response to corticosteroid treatment. Invest Ophthalmol Vis Sci. 2012;53:267–272.
   PubMed Web of Science ®Google Scholar
• Borkar DS, Fleiszig SM, Leong C, et al. Association between cytotoxic and invasive Pseudomonas aeruginosa and clinical outcomes in bacterial keratitis. JAMA Ophthalmol. 2013;131:147–153.
   PubMed Web of Science ®Google Scholar
• Ni N, Srinivasan M, McLeod SD, et al. Use of adjunctive topical corticosteroids in bacterial keratitis. Curr Opin Ophthalmol. 2016. Epub 2016 Apr 19. doi:10.1097/ICU.0000000000000273.
   PubMed Web of Science ®Google Scholar
• Brandt CR. Peptide therapeutics for treating ocular surface infections. J Ocul Pharmacol Ther. 2014;30:691–699.
   PubMed Web of Science ®Google Scholar
• Wu M, McClellan SA, Barrett RP, et al. Beta-defensins 2 and 3 together promote resistance to Pseudomonas aeruginosa keratitis. J Immunol. 2009;183:8054–8060.
   PubMed Web of Science ®Google Scholar
• Szliter E, Lighvani S, Barrett RP, et al. Vasoactive intestinal peptide balances pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected cornea and protects against corneal perforation. J Immunol. 2007;178:1105–1114.
   PubMed Web of Science ®Google Scholar
• Li SA, Liu J, Xiang Y, et al. Therapeutic potential of the antimicrobial peptide OH-CATH30 for antibiotic-resistant Pseudomonas aeruginosa keratitis. Antimicrob Agents Chemother. 2014;58:3144–3150.
   PubMed Web of Science ®Google Scholar
• McClellan SA, Ekanayaka SA, Li C, et al. Thrombomodulin protects against bacterial keratitis, is anti-inflammatory, but not angiogenic. Invest Ophthalmol Vis Sci. 2015;56:8091–8100.
   PubMed Web of Science ®Google Scholar
• Lim A, Wenk MR, Tong L. Lipid-based therapy for ocular surface inflammation and disease. Trends Mol Med. 2015;21:736–748.
   PubMed Web of Science ®Google Scholar
• Sun Y, Pearlman E. Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564). Invest Ophthalmol Vis Sci. 2009;50:1247–1254.
   PubMed Web of Science ®Google Scholar
• McClellan S, Jiang X, Barrett R, et al. High-mobility group box 1: a novel target for treatment of Pseudomonas aeruginosa keratitis. J Immunol. 2015;94:1776–1787.
   Web of Science ®Google Scholar
• Yang K, Wu M, Li M, et al. miR-155 suppresses bacterial clearance in Pseudomonas aeruginosa-induced keratitis by targeting Rheb. J Infect Dis. 2014;210:89–98.
   PubMed Web of Science ®Google Scholar
• Lumayag S, Haldin CE, Corbett NJ, et al. Inactivation of the microRNA-183/96/182 cluster results in syndromic retinal degeneration. PNAS. 2013;110(6):e507–e516.
   PubMed Web of Science ®Google Scholar
• Muraleedharan CK, McClellan SA, Barrett RP, et al. Inactivation of the miR-183/96/182 cluster decreases the severity of Pseudomonas aeruginosa-induced keratitis. Invest Ophthalmol Vis Sci. 2016;57:1506–1517.
   PubMed Web of Science ®Google Scholar
• Bamdad S, Malekhosseini H, Khosravi A. Ultraviolet A/riboflavin collagen cross-linking for treatment of moderate bacterial corneal ulcers. Cornea. 2015;34(4):402–406.
   PubMed Web of Science ®Google Scholar
• Chan TCY, Lau TWS, Lee JWY, et al. Corneal collagen cross-linking for infectious keratitis: an update of clinical studies. Acta Ophthalmol. 2015;93:689–696.
   PubMed Web of Science ®Google Scholar
• Young RC, Hodge DO, Liesegang TJ, et al. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976–2007: the effect of oral antiviral prophylaxis. Arch Ophthalmol. 2010;128(9):1178–1183.
   PubMedGoogle Scholar
• Shimeld C, Hill TJ, Blyth WA, et al. Reactivation of latent infection and induction of recurrent herpetic eye disease in mice. J Gen Virol. 1990;71(Pt 2):397–404.
   PubMed Web of Science ®Google Scholar
• Liesegang TJ. Classification of herpes simplex virus keratitis and anterior uveitis. Cornea. 1999;18(2):127–143.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Schwartz GS. Classification of herpes simplex virus keratitis. Cornea. 1999;18(2):144–154.
   PubMed Web of Science ®Google Scholar
• Barron BA, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis. Ophthalmology. 1994;101(12):1871–1882.
   PubMed Web of Science ®Google Scholar
• Wilhelmus KR, Gee L, Hauck WW, et al. Herpetic Eye Disease Study. A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology. 1994;101(12):1883–1895; discussion 1895–1886.
   Web of Science ®Google Scholar
• Jabs DA. Acyclovir for recurrent herpes simplex virus ocular disease. N Engl J Med. 1998;339(5):340–341.
   PubMed Web of Science ®Google Scholar
• Conrady CD, Zheng M, Mandal NA, et al. IFN-alpha-driven CCL2 production recruits inflammatory monocytes to infection site in mice. Mucosal Immunol. 2013;6(1):45–55.
   PubMed Web of Science ®Google Scholar
• Frank GM, Buela KA, Maker DM, et al. Early responding dendritic cells direct the local NK response to control herpes simplex virus 1 infection within the cornea. J Immunol. 2012;188(3):1350–1359.
   PubMed Web of Science ®Google Scholar
• Conrady CD, Zheng M, Fitzgerald KA, et al. Resistance to HSV-1 infection in the epithelium resides with the novel innate sensor, IFI-16. Mucosal Immunol. 2012;5(2):173–183.
   PubMed Web of Science ®Google Scholar
• Conrady CD, Zheng M, Stone DU, et al. CD8+ T cells suppress viral replication in the cornea but contribute to VEGF-C-induced lymphatic vessel genesis. J Immunol. 2012;189(1):425–432.
   PubMed Web of Science ®Google Scholar
• Doymaz MZ, Rouse BT. Herpetic stromal keratitis: an immunopathologic disease mediated by CD4+ T lymphocytes. Invest Ophthalmol Vis Sci. 1992;33(7):2165–2173.
   PubMed Web of Science ®Google Scholar
• Buela KA, Hendricks RL. Cornea-infiltrating and lymph node dendritic cells contribute to CD4+ T cell expansion after herpes simplex virus-1 ocular infection. J Immunol. 2015;194(1):379–387.
   PubMed Web of Science ®Google Scholar
• Suryawanshi A, Veiga-Parga T, Rajasagi NK, et al. Role of IL-17 and Th17 cells in herpes simplex virus-induced corneal immunopathology. J Immunol. 2011;187(4):1919–1930.
   PubMed Web of Science ®Google Scholar
• Maertzdorf J, Osterhaus AD, Verjans GM. IL-17 expression in human herpetic stromal keratitis: modulatory effects on chemokine production by corneal fibroblasts. J Immunol. 2002;169(10):5897–5903.
   PubMed Web of Science ®Google Scholar
• Sehrawat S, Rouse BT. Anti-inflammatory effects of FTY720 against viral-induced immunopathology: role of drug-induced conversion of T cells to become Foxp3+ regulators. J Immunol. 2008;180(11):7636–7647.
   PubMed Web of Science ®Google Scholar
• Gaddipati S, Estrada K, Rao P, et al. IL-2/anti-IL-2 antibody complex treatment inhibits the development but not the progression of herpetic stromal keratitis. J Immunol. 2015;194(1):273–282.
   PubMed Web of Science ®Google Scholar
• Suryawanshi A, Mulik S, Sharma S, et al. Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor. J Immunol. 2011;186(6):3653–3665.
   PubMed Web of Science ®Google Scholar
• Gimenez F, Mulik S, Veiga-Parga T, et al. Robo 4 counteracts angiogenesis in herpetic stromal keratitis. PLoS One. 2015;10(12):e0141925.
   Web of Science ®Google Scholar
• Mulik S, Xu J, Reddy PB, et al. Role of miR-132 in angiogenesis after ocular infection with herpes simplex virus. Am J Pathol. 2012;181(2):525–534.
   PubMed Web of Science ®Google Scholar
• Wuest TR, Carr DJ. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis. J Exp Med. 2010;207(1):101–115.
   PubMed Web of Science ®Google Scholar
• Bryant-Hudson KM, Gurung HR, Zheng M, et al. Tumor necrosis factor alpha and interleukin-6 facilitate corneal lymphangiogenesis in response to herpes simplex virus 1 infection. J Virol. 2014;88(24):14451–14457.
   PubMed Web of Science ®Google Scholar
• Hamrah P, Cruzat A, Dastjerdi MH, et al. Corneal sensation and subbasal nerve alterations in patients with herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology. 2010;117(10):1930–1936.
   PubMed Web of Science ®Google Scholar
• Yun H, Rowe AM, Lathrop KL, et al. Reversible nerve damage and corneal pathology in murine herpes simplex stromal keratitis. J Virol. 2014;88(14):7870–7880.
   PubMed Web of Science ®Google Scholar
• Chucair-Elliott AJ, Zheng M, Carr DJ. Degeneration and regeneration of corneal nerves in response to HSV-1 infection. Invest Ophthalmol Vis Sci. 2015;56(2):1097–1107.
   PubMed Web of Science ®Google Scholar
• Hamrah P, Sahin A, Dastjerdi MH, et al. Cellular changes of the corneal epithelium and stroma in herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology. 2012;119(9):1791–1797.
   PubMed Web of Science ®Google Scholar
• Divito SJ, Hendricks RL. Activated inflammatory infiltrate in HSV-1-infected corneas without herpes stromal keratitis. Invest Ophthalmol Vis Sci. 2008;49(4):1488–1495.
   PubMed Web of Science ®Google Scholar